How Social Media Became a Storefront for Illegal Drugs and Unregulated Weight-Loss Injections

There was a time when buying an illegal drug meant meeting someone in a parking lot, or knowing a guy who knew a guy. That barrier, however uncomfortable, at least slowed things down. It doesn't exist anymore. Today, a teenager scrolling TikTok on a school night can order cocaine, Xanax, or Adderall with the same ease as ordering a phone case.

A recent investigation by Forbes confirmed what many young people already know from experience: TikTok has quietly become one of the largest marketplaces for illegal dealers selling street drugs and controlled substances. The platform's own guidelines ban the promotion or sale of illegal drugs and paraphernalia. But enforcement has been so weak that sellers have been able to buy targeted ads aimed at users who simply expressed interest in categories like education or shopping. Think of it like a store that posts "no shoplifting" signs while leaving the back door unlocked all night.

Street drugs are only part of the problem. Over the past year, counterfeit and mass-compounded weight-loss drugs have flooded social feeds, pushed by false testimonials and slick marketing language. One of the most concerning examples is retatrutide, an investigational molecule still working its way through clinical trials. It has not received FDA approval. Yet online wellness companies and medical spas are advertising illegally compounded versions of it on Facebook, Instagram, and TikTok, promising "jaw dropping results" and, in one case, "three times the fat-fighting horsepower in one clean, clinical ride."

That language is designed to sound clinical. It is not. What these sellers rarely mention is where the product actually comes from: unregistered foreign suppliers and unvetted facilities operating entirely outside the U.S. regulatory system. Buyers see phrases like "third-party validation," but they have no real way to confirm what's in the vial, where it was made, or whether the dose is even close to accurate. It's a bit like buying a parachute from someone who assures you it's "basically" tested.

For a growing number of patients, that uncertainty has turned into a medical emergency. Health officials in Victoria, Australia have documented toxicity linked to unapproved peptide retatrutide, including severe hospitalizations and acute liver failure. In the United States, one 25-year-old man ended up in the emergency room three times after taking the drug, suffering cardiac complications and severe stomach distress, according to CBS News. These are not abstract statistics. They are people who thought they were doing something responsible for their health and instead landed in a hospital bed.

Why Doctors Are Caught in the Middle

As a compounding pharmacist of more than 50 years, I've watched this crisis unfold from an unusual vantage point: the space between the pharmacy counter and the exam room. And I can say with confidence that the front line of this problem isn't social media companies or federal regulators. It's the doctor's office.

Here's the uncomfortable part. Physicians and other healthcare providers are, by a wide margin, the most trusted voice when patients decide where to buy medicine online. A 2025 survey by the Alliance for Safe Online Pharmacies found that 49% of Americans who purchase drugs online say a practitioner recommended a specific source. That's more influence than pharmacists have. More than health insurers. More than family and friends combined.

Yet most providers have never been trained for this moment. According to research cited by the BeSafe Rx symposium, only 2% of practitioners have received any training on identifying counterfeit medicines or counseling patients about them. Eighty-nine percent say they don't know what actions they could even take if a patient brought it up. This isn't a failure of individual commitment. It's a systemic gap. We've asked providers to referee a fight they were never given the rulebook for.

The patients buying retatrutide through social media, medical spas, or telehealth platforms don't see themselves as taking a risk. Many genuinely believe they're getting a clinically validated product, not something sourced from an unregistered overseas facility. That distinction matters enormously in a clinical setting. A patient who shows up with unexplained cardiac symptoms or stomach distress may not think to mention the injections they've been buying online, because in their mind, it was never relevant to begin with. They thought it was medicine. It just wasn't the kind their doctor could vouch for.

That's exactly where providers can make a difference, and it doesn't require becoming a pharmacology expert overnight. Simply asking patients where they obtain their medicines opens the door to a fuller clinical picture. When something seems off, pointing patients toward an authoritative verification resource, such as the National Association of Boards of Pharmacy's safe.pharmacy tool, takes minutes and requires no specialized training. And helping patients understand the real difference between an FDA-approved alternative and an unregulated compound sourced from an unvetted supplier can be the conversation that prevents a hospital visit.

None of this fixes the underlying problem of platforms failing to enforce their own rules. It doesn't replace the work regulators and lawmakers need to do to close these markets down. But it does something regulation alone cannot: it reaches the patient at the moment they're most vulnerable, sitting across from someone they trust.

Why It Matters

The black market for retatrutide, and for counterfeit medicines more broadly, won't be shut down by platforms, regulators, or lawmakers acting alone. Social media companies have shown limited appetite for aggressive enforcement, and regulatory crackdowns take time that patients in crisis don't have. Healthcare providers occupy a different kind of leverage point entirely. They're not gatekeepers in the traditional sense. They're the person a patient calls when something feels wrong.

That trust is worth protecting, and worth using. A single question asked in an exam room, about where a medication came from, can surface a risk that no algorithm or ad-review team caught. Until platforms tighten enforcement and regulators catch up to the pace of these markets, providers remain one of the most powerful interventions available, not because the system was built that way, but because patients still believe in them. That belief deserves to be met with better preparation, not left to chance.